|
KMID : 0624620140470030122
|
|
BMB Reports
2014 Volume.47 No. 3 p.122 ~ p.129
|
|
|
4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
|
|
Vinay Dass S.
Kwon Byoung-S.
|
|
|
Abstract
|
|
|
|
Although considerable progress has been made in understanding how tumors evade immune surveillance, measures to counter the same have not kept pace with the advances made in designing effective strategies. 4-1BB (CD137; TNFRS9), an activation-induced costimulatory molecule, is an important regulator of immune responses. Targeting 4-1BB or its natural ligand 4-1BB ligand (4-1BBL) has important implications in many clinical conditions, including cancer. In-depth analysis revealed that 4-1BB-mediated anti-cancer effects are based on its ability to induce activation of cytotoxic T lymphocytes (CTL), and among others, high amounts of IFN-γ. In this review, we will discuss the various aspects of 4-1BB-mediated anti-tumor responses, the basis of such responses, and future directions.
|
|
|
KEYWORD
|
|
|
Immunotherapy, Tumor, 4-1BB
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|